ADHD Stimulant Medications: Comparative Overview and Selection Guide
Stimulant Classes
| Class | Formulations (Brand/Generic) | Duration | Key Features |
|---|---|---|---|
| Methylphenidate (MPH) | Ritalin IR, Ritalin LA, Concerta (OROS), Daytrana (patch), Focalin XR (d-MPH), Metadate CD, Quillivant XR (liquid) | 4–12 h | First-line; multiple delivery systems; d-MPH (Focalin) = 2× potency |
| Mixed Amphetamine Salts (MAS) | Adderall IR/XR, Mydayis (16 h) | 4–16 h | d- & l-amphetamine; slightly more norepinephrine effect |
| Lisdexamfetamine (Vyvanse) | Prodrug → d-amphetamine | 10–14 h | Lower abuse potential (requires hydrolysis); consistent absorption |
| Dextroamphetamine | Dexedrine IR/Spansule, Zenzedi, ProCentra (liquid) | 4–10 h | Pure d-isomer |
Non-Stimulant Options (Often Adjunctive)
- Guanfacine XR (Intuniv): α₂A agonist – improves prefrontal regulation; sedation, hypotension.
- Clonidine XR (Kapvay): α₂ agonist – more sedating; helpful for aggression, tics, sleep.
- Atomoxetine (Strattera): NRI – 4–6 weeks onset; no abuse potential.
- Viloxazine (Qelbree): NRI + serotonin modulation; newer.
Selection Factors
- Age, comorbidities (anxiety, tics, cardiac, substance use), duration needed, swallowing ability, insurance formulary, side effect profile, patient/family preference.
- Trial: Start low, titrate weekly; monitor height, weight, BP, HR, sleep, appetite.
~70–80% respond to first stimulant tried; most non-responders respond to the other class.
Prescription Medications - Related Articles
- Patient Identification Before Medication: Two-Identifier Protocol
- High HGH Levels: Symptoms, Causes & Potential Risks
- Safe Injection Techniques for Extended-Release Medications
- Chantix and Pregnancy: Risks & Safety Concerns
- Nexium and Cholesterol: What You Need to Know
- Medical Uses of Opioids: Indications, Mechanisms & Risk Mitigation
- Ritalin (Methylphenidate): Uses, Benefits & Side Effects
